Related Experiment Video
Updated: May 6, 2026

08:28
Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers
Published on: September 19, 2017
7.6K
G-quadruplexes as potential therapeutic targets for embryonal tumors
Tarek Shalaby1, Giulio Fiaschetti, Kazuo Nagasawa
1Division of Oncology, University Children's Hospital of Zurich, Zurich 8032, Switzerland. tarek.shalaby@kispi.uzh.ch.
Molecules (Basel, Switzerland)
|October 25, 2013
Summary
G-quadruplexes, structures in G-rich DNA, show promise as novel anticancer drugs for embryonal tumors. Targeting these DNA structures offers a new therapeutic strategy for difficult-to-treat childhood cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Embryonal tumors are highly malignant pediatric neoplasms with high mortality.
- G-quadruplexes are special DNA structures found in telomeres and oncogene regulatory regions like MYC.
- Telomeres and MYC are crucial in cancer cell biology, making G-quadruplexes attractive therapeutic targets.
Purpose of the Study:
- To review DNA-targeted cancer therapy approaches.
- To summarize recent advancements in G-quadruplex ligands as anticancer drugs.
- To explore the future potential of G-quadruplexes for treating nervous system embryonal tumors.
Main Methods:
- Literature review of DNA-targeted cancer therapies.
- Analysis of recent developments in G-quadruplex ligand research.
- Discussion of preclinical and clinical data for G-quadruplex targeting agents.
Main Results:
- G-quadruplex ligands have demonstrated promising anticancer activity in preclinical models.
- Some G-quadruplex-targeting compounds have progressed to Phase II clinical trials.
- The review synthesizes current knowledge on G-quadruplexes in oncology.
Conclusions:
- G-quadruplexes represent a promising frontier for novel anticancer drug development.
- Targeting G-quadruplex structures offers a potential new therapeutic strategy for embryonal tumors.
- Further research into G-quadruplex ligands could lead to improved treatments for pediatric cancers.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K

